Literature DB >> 22341781

Crystal structures of murine norovirus-1 RNA-dependent RNA polymerase in complex with 2-thiouridine or ribavirin.

Intekhab Alam1, Ji-Hye Lee, Ki Joon Cho, Kang Rok Han, Jai Myung Yang, Mi Sook Chung, Kyung Hyun Kim.   

Abstract

Murine norovirus-1 (MNV-1) shares many features with human norovirus (HuNoV) and both are classified within the norovirus genus of Caliciviridae family. MNV-1 is used as the surrogate for HuNoV research since it is the only form that can be grown in cell culture. HuNoV and MNV-1 RNA dependent RNA polymerase (RdRp) proteins with the sequence identity of 59% show essentially identical conformations. Here we report the first structural evidence of 2-thiouridine (2TU) or ribavirin binding to MNV-1 RdRp, based on the crystal structures determined at 2.2Å and 2.5Å resolutions, respectively. Cellular and biochemical studies revealed stronger inhibitory effect of 2TU on the replication of MNV-1 in RAW 264.7 cells, compared to that of ribavirin. Our complex structures highlight the key interactions involved in recognition of the nucleoside analogs which block the active site of the viral RNA polymerase. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341781     DOI: 10.1016/j.virol.2012.01.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Antiviral activities of Artemisia princeps var. orientalis essential oil and its α-thujone against norovirus surrogates.

Authors:  Mi Sook Chung
Journal:  Food Sci Biotechnol       Date:  2017-08-28       Impact factor: 2.391

Review 2.  Current tools for norovirus drug discovery.

Authors:  Sahani Weerasekara; Allan M Prior; Duy H Hua
Journal:  Expert Opin Drug Discov       Date:  2016-05-02       Impact factor: 6.098

3.  The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency.

Authors:  Jeremy M Woodward; Effrossyni Gkrania-Klotsas; Anthony Yk Cordero-Ng; Aloysious Aravinthan; Betty N Bandoh; Hongxiang Liu; Susan Davies; Hongyi Zhang; Philip Stevenson; Martin D Curran; Dinakantha Kumararatne
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

4.  Hydrophobic and charged residues in the C-terminal arm of hepatitis C virus RNA-dependent RNA polymerase regulate initiation and elongation.

Authors:  Amy L Cherry; Caitriona A Dennis; Andrew Baron; Leslie E Eisele; Pia A Thommes; Joachim Jaeger
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

5.  Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase.

Authors:  Holly Freedman; Juthika Kundu; Egor Petrovitch Tchesnokov; John Lok Man Law; James A Nieman; Raymond F Schinazi; D Lorne Tyrrell; Matthias Gotte; Michael Houghton
Journal:  J Chem Inf Model       Date:  2020-12-01       Impact factor: 4.956

6.  In silico and in vitro evaluation of silibinin: a promising anti-Chikungunya agent.

Authors:  Sudip Kumar Dutta; Siddhartha Sengupta; Anusri Tripathi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-04-05       Impact factor: 2.416

Review 7.  Treatment of norovirus infections: moving antivirals from the bench to the bedside.

Authors:  Stuart S Kaufman; Kim Y Green; Brent E Korba
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970

Review 8.  Recent Advances in the Discovery of Norovirus Therapeutics.

Authors:  Yunjeong Kim; Anushka C Galasiti Kankanamalage; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2015-08-17       Impact factor: 7.446

Review 9.  Anti-norovirus therapeutics: a patent review (2010-2015).

Authors:  Anushka C Galasiti Kankanamalage; Pathum M Weerawarna; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

10.  Effects of Oils and Essential Oils from Seeds of Zanthoxylum schinifolium against Foodborne Viral Surrogates.

Authors:  Mi Oh; Mi Sook Chung
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.